Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Marginal zone lymphoma
Marginal zone lymphoma
Marginal zone lymphoma
Drug discovery
15
drugs
With orphan designations
Rare oncological diseases
Marginal zone lymphoma
Overview
Marginal zone lymphoma (MZL) is a rare, indolent B-cell non-Hodgkin lymphoma arising from marginal zone B cells, comprising three subtypes: extranodal (MALT lymphoma), nodal, and splenic. It is often linked to chronic antigen stimulation (e.g., H. pylori infections, autoimmune disorders) and exhibits heterogeneous clinical behavior. Diagnosis requires integrating histopathology, molecular testing (e.g., MALT1 translocations), and staging. Treatment ranges from anti-infective therapies for localized disease to immunochemotherapy for advanced stages, with prognosis varying by subtype and risk stratification [1][5][12].
Population
Burden
Survival: 5-year relative survival ranges from 76.5% (nodal) to 93.8% (MALT) [4][7].
Prognostic challenges: Early progression (POD24) and histologic transformation to aggressive lymphoma correlate with poorer outcomes [1][12].
Economic impact: High treatment costs for relapsed/refractory cases, with immunochemotherapy and hospitalizations driving expenses [14][19].
Therapies
Localized disease: H. pylori eradication for gastric MALT; involved-site radiation (24–30 Gy) for non-responsive/extranodal cases [3][5][13].
Advanced disease: Rituximab-based regimens (e.g., bendamustine-rituximab), lenalidomide-rituximab (R2), or splenectomy/splenic radiation for splenic MZL [8][13][17].
Asymptomatic cases: Active surveillance until progression or symptom onset [6][12].
Categories: rare hematological diseases, rare neoplastic diseases, rare transplant-related disorders
Research Papers
1,329 drug discovery papers about Marginal zone lymphoma, with 3 first-in-class and 16 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,329 drug discovery papers about Marginal zone lymphoma, with 3 first-in-class and 16 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-25 | Choroidal Involvement in Nodal Marginal Zone Lymphoma Presenting as Serous Retinal Detachment.
To describe the clinical presentation and multimodal imaging findings of choroidal involvement in nodal marginal zone lymphoma (NMZL) presenting as serous retinal detachment and its response to systemic chemotherapy. Retrospective review of clinical records and multimodal imaging findings, with joint interpretation by a uveitis specialist and the hematology-oncology team. A 63-year-old woman presented with decreased vision in the left eye and was found to have a shallow serous retinal detachment. Inflammatory choroiditis was initially suspected and systemic corticosteroids therapy was initiated, resulting in transient improvement. Subsequent examination revealed recurrent subretinal fluid with multiple subretinal yellow infiltrates and diffuse choroidal thickening after the steroid effect subsided. Optical coherence tomography demonstrated undulating retinal pigment epithelium. Choroidal lymphoma was considered, prompting thorough systemic investigation. Systemic imaging later identified axillary and intra-abdominal lymphadenopathy and a right breast mass. Histopathology of the breast lesion confirmed NMZL. The patient was treated with rituximab-based systemic chemotherapy with intrathecal chemotherapy, achieving partial systemic response and complete ocular remission. Choroidal involvement in NMZL is rare and may present as steroid-responsive but recurrent serous retinal detachment, mimicking inflammatory disease. Systemic evaluation with biopsy of accessible extraocular sites, in conjunction with compatible ocular findings, can establish the diagnosis while avoiding high-risk choroidal biopsy. Early recognition and multidisciplinary collaboration are essential to enable timely diagnosis and systemic treatment.
2026-09-06 | First-line therapy and maintenance outcomes in Chinese patients with marginal zone lymphoma: a multicenter retrospective analysis with prognostic implications for chemotherapy decision-making.
This multicenter retrospective study evaluated first-line treatment patterns, maintenance therapy outcomes, and prognostic factors in 171 newly diagnosed marginal zone lymphoma (MZL) patients treated across multiple centers in Fujian Province, China (2019-2024). The MALT subtype predominated (79.0%), with the gastrointestinal tract and lung being the most common primary sites. The first-line overall response rate was 91.1%, with 67.3% of patients achieving complete remission. Five-year progression-free survival (PFS) and overall survival (OS) were 82.6% and 94.7%, respectively. Maintenance therapy, received by 66.1% of patients, was associated with superior 5-year OS (100% vs. 87.5%, P=0.0104). Multivariate analysis identified Ki-67 >20% (HR=3.208, P=0.024) and high tumor burden (HR=4.670, P=0.003) as independent negative predictors for PFS, while high tumor burden (HR=4.493, P=0.004) and B symptoms (HR=3.324, P=0.030) predicted worse OS. Chinese MZL patients demonstrated favorable outcomes, and maintenance therapy conferred a significant OS benefit. Ki-67, tumor burden, and B symptoms serve as practical prognostic indicators to inform risk stratification and personalized treatment planning.
2026-09-03 | BRAF V600E-mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia.
To establish the occurrence of BRAF mutation in marginal zone lymphomas (MZLs) and study its impact on clinical presentation, pathologic features, and disease classification. Conventional histology, immunohistochemistry, flow cytometry, and molecular methods were used. We identified 2 BRAF‑mutated MZL cases: a nodal MZL (NMZL) with BRAF V600E and partial morphologic/immunophenotypic overlap with hairy cell leukemia (HCL) and an extranodal MZL with a non-V600E BRAF mutation co‑occurring with TET2, KRAS, and TP53 variants. The NMZL case showed strong CD25 and CD123 expression and patchy cyclin D1 expression; together with the presence of a BRAF V600E mutation, these features overlapped with HCL. However, the absence of annexin A1 and CD103 expression, along with the remaining morphologic features in the lymph node, supported accurate classification as NMZL. These 2 cases expand the mutational spectrum of MZL and illustrate important diagnostic pitfalls. These observations underscore that BRAF V600E, while highly specific and clinically useful for HCL in the context of a B‑cell lymphoproliferative process involving blood and marrow, is not entirely pathognomonic and must be interpreted alongside morphology and a full immunophenotypic panel. Integrating BRAF testing into the workup of challenging small B‑cell lymphomas may refine diagnosis and reveal rare, potentially targetable MAPK pathway lesions.
2026-08-25 | Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma.
There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase II MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R/R MZL treated with zanubrutinib after at least one prior anti-CD20-based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), MALT (18.9%), nodal (19.8%), and non-classifiable (6%). The median number of prior lines of therapy (LoT) was 1.5 (range 1-7); 26% were refractory to the immediately preceding line, and 59% were POD24 to frontline. Thirty-one patients (26.3%) would not have met MAGNOLIA eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA eligibility. Fewer prior LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than cases with progressing disease (p < 0.01). Adverse events (AEs) were reported in 34.1% of patients (grade ≥ 3 in 14.4%). MAGNOLIA-ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (p = 0.04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R/R MZL, with improved outcomes when administered earlier in the disease.
2026-08-02 | NLRC5-Deficient Macrophages Promote a Tumor-Permissive Phenotype via AXL- and MERTK-Mediated Efferocytosis.
The innate immune protein NLRC5 plays a key role in cancer immune surveillance. Reduced NLRC5 expression is associated with a poor prognosis for many types of cancers. Previously, we showed that mice with a myeloid-specific deletion of Nlrc5 (Nlrc5mø-KO) develop gastric lymphoid lesions to Helicobacter infection resembling early-stage marginal zone lymphoma. We hypothesized that NLRC5 deficiency may promote a tumor-permissive microenvironment mediated by tumor-associated macrophages (TAMs). Consistent with this hypothesis, splenic macrophages from Helicobacter-infected Nlrc5mø-KO mice had upregulated expression of genes encoding the TAM receptor tyrosine kinases, Axl and Mertk. The levels of AXL and MERTK gene expression and MERTK phosphorylation were increased in NLRC5-/- THP-1 macrophages when compared with WT cells. In response to Helicobacter stimulation, Nlrc5-/- macrophages had significantly elevated anti-inflammatory responses (IL-10, TGF-β, Socs1, Socs3) compared with WT cells. Importantly, Nlrc5-/-macrophages showed enhanced efferocytosis and reduced antigen presentation to CD8+ T cells. Pretreatment of macrophages with AXL and MERTK inhibitors (R428, UNC2025) resulted in reduced efferocytosis and phosphorylation of downstream signaling molecules, STAT3 and ERK1/2. We propose that defective NLRC5 signaling in macrophages leads to tumor-permissive responses, thereby promoting the development of gastric lymphoid neogenesis to Helicobacter infection.
cell therapies
2026-08-31 | Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.
While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL. The primary end-point was progression-free survival from first relapse (2PFS), with survival after relapse (SAR) as the secondary end-point. The median 2PFS was 24 months, with a 2-year 2PFS rate of 49% and a 2-year SAR rate of 66%. Multivariable analysis identified advanced age, progression of disease within 24 months (POD24) and high MZL International Prognostic Index (MZL-IPI) scores as significant predictors of inferior survival. Patients with splenic and disseminated subtypes also demonstrated worse outcomes. Relapse following systemic therapy often marks a transition to an aggressive clinical course. Time to progression and the MZL-IPI are robust tools for risk stratification, highlighting an urgent need for novel therapeutic strategies for high-risk relapsed MZL populations.
2026-08-28 | CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell non-Hodgkin lymphoma, but centralised manufacturing-with its complex logistics and long vein-to-vein times-drives up costs and restricts access. We aimed to evaluate the safety of GLPG5101, a fresh, CD19 CAR T-cell product manufactured through a decentralised process, and determine the recommended phase 2 dose. This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study, was executed in five hospitals in the Netherlands and Belgium. Patients aged 18 years or older, with histologically confirmed diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) after two or more lines of therapy, measurable disease according to the Lugano classification, Eastern Cooperative Oncology Group Performance Status 0-2, and adequate organ function were enrolled. Patients were treated with a single intravenous infusion at one of three dose levels of GLPG5101 (dose level 1 [35-50 × 106 viable CAR+ T-cells], dose level 2 [85-110 × 106 viable CAR+ T-cells], and dose level 3 [200-250 × 106 viable CAR+ T-cells]). The phase 1 part of the study applied a Bayesian Optimal Interval design and the primary endpoints were safety (incidence of adverse events and serious adverse events until end of treatment [week 14], and dose-limiting toxicities [DLTs] until day 28) in patients who received fresh GLPG5101 at any dose (excluding recipients of non-conforming product [not meeting prespecified release criteria other than dose]) and determination of the recommended phase 2 dose. The study was registered with ClinicalTrials.gov (NCT06561425) and is closed for recruitment. From March 15, 2022, to Sept 10, 2024, 27 patients were screened for eligibility, 24 of whom were enrolled, underwent leukapheresis and lymphodepleting chemotherapy and received GLPG5101. Data cutoff was June 1, 2025. In the intention-to-treat population (n=24), the median age was 66·5 years (IQR 59·0-71·5), 15 (63%) patients were male, nine (38%) were female, and 21 (88%) were White. One of the 24 patients received a non-conforming product and was excluded from the safety analysis population. Median follow-up was 24·0 months (IQR 20·7-24·9). Five DLTs were reported: grade 3 thrombocytopenia (n=1, dose level 1), death from intra-abdominal haemorrhage (n=1, dose level 2), and grade 4 prolonged neutropenia not resolving to grade 2 or lower within 28 days (n=1 at dose level 1 and n=2 at dose level 2). All 23 patients in the safety analysis population had grade 3 or higher treatment-emergent adverse events; the most common were neutropenia (22 [96%]), leukopenia (nine [39%]), lymphopenia (seven [30%]), anaemia (six [26%]), and thrombocytopenia (five [22%]). Treatment-related deaths occurred in four patients: one during the 14-week treatment period due to intra-abdominal haemorrhage, and three after the treatment period due to Escherichia coli sepsis (n=1), immune-effector cell-associated haemophagocytic lymphohistiocytic syndrome (n=1), and COVID-19 (n=1). The safety review committee selected 110 × 106 (range 50-110 × 106) viable CAR T-cells as the recommended phase 2 dose. The results of this study showed the feasibility of rapid multicentre decentralised manufacturing and delivery of fresh CAR T-cell therapy in heavily pretreated B-cell non-Hodgkin lymphoma. The phase 2 part of ATALANTA-1 will provide further information on clinical activity and safety. CellPoint, Lakefront Biotherapeutics.
2026-08-05 | A 13-Year Review of Non-Diffuse Large B Cell Lymphomas of the Central Nervous System at a Tertiary Hospital: A Case Series Study.
Non-diffuse large B-cell lymphomas (non-DLBCL) of the central nervous system (CNS) are rare and diagnostically challenging. This study aims to characterize the clinical, radiological, and pathological features of non-DLBCL CNS lymphomas diagnosed at a tertiary care center over 13 years, highlighting diagnostic pitfalls. A retrospective review was conducted of non-DLBCL CNS lymphoma cases diagnosed at Sunnybrook Health Sciences Centre, Toronto, from 2010 to 2022. Clinical, demographic, and radiological data were extracted from medical records. Imaging was reviewed by a neuroradiologist, and histopathological slides and molecular data were re-evaluated by a pathology team. Additional tests were performed to update classifications per the 5th edition of the WHO Classification of Haematolymphoid Tumors. Seventeen cases were identified (11 males, 6 females; age 38-76), compared to 72 DLBCL cases during the same period. Nine cases were extra-axial and eight intra-axial. Eight were primary and nine secondary CNS lymphomas. B-cell lymphomas (n = 13) included extra-nodal marginal zone lymphoma (n = 6), follicular lymphoma, mantle cell lymphoma, CLL, intravascular large B-cell lymphoma (n = 2), EBV+ LBCL, and polymorphic PTLD. T-cell lymphomas (n = 4) included PTCL, NOS (n = 2), ALK-negative ALCL, and secondary mycosis fungoides. Imaging revealed four major patterns, and symptoms were largely due to mass effect. This case series emphasizes the considerable heterogeneity of non-DLBCL CNS lymphomas and the diagnostic challenges they present. It highlights key features that can aid recognition and improve diagnostic accuracy for these rare CNS entities. Trial Registration: SUN-5771.
2026-05-27 | Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy with notable genetic, epigenetic, and clinical heterogeneity. This study utilized coding and non-coding sequencing (n=74), including whole-genome sequencing (WGS) on 24 paired tumour-normal samples, targeted sequencing (n=55) and DNA methylation in 126 cases to characterize the disease. From WGS, we identified recurrent, predominantly clonal, coding mutations in KLF2 (50%), KMT2D (25%) and NOTCH2 (25%), alongside rare mutations in FLNC (8%), novel mutations in FAM135B (17%) and non-coding mutational hotspots in BCL6, PAX5 and BACH2, linked to aberrant somatic hypermutation. At least one non-coding hotspot was detected in 69% of cases. Copy-number aberrations (CNAs) were present in 73% of cases, including del(7q) (27%), gain(3q) (17%) and trisomy 12 (13%). DNA methylation profiling revealed two epigenetic subgroups: SMZL-HR (high-risk, n=67) and SMZL-LR (low-risk, n=59). SMZL-HR was associated with adverse features such as female sex, IGHV1-2*04 usage, KLF2 mutations, del(7q), shorter telomeres, and elevated epiCMIT scores. Transcriptomic analysis highlighted enhanced cell proliferation in SMZL-HR, with enrichment of E2F and G2M checkpoint pathways and epigenetic regulation via EZH2. SMZL-HR patients had significantly shorter time to first treatment (TTFT) (HR: 1.9, p=.003) and reduced overall survival (HR: 2.5, p=.039): 85% of SMZL-HR patients required treatment and showed a higher frequency of transformation (p=.007) and mortality (p<.001). Multivariate analysis confirmed SMZL-HR as an independent predictor of shorter TTFT (HR: 2.4, p=.001). These findings demonstrate the role of DNA methylation and molecular profiling in SMZL risk stratification.
2026-05-08 | [Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma].
To analyze the clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue (MALT) lymphoma transformed into diffuse large B-cell lymphoma (DLBCL). A retrospective analysis was performed on patients diagnosed with MALT lymphoma at Henan Provincial People's Hospital from January 2016 to December 2025. According to whether DLBCL transformation occurred, the patients were divided into the transformed group (MALT lymphoma patients who developed DLBCL transformation) and the non-transformed group. The patients were followed up until December 30, 2025, and the clinical and genetic characteristics were compared between the two groups. A total of 175 patients were included, including 13 patients in the transformation group, 4 males and 9 females, aged (58±18) years; and 162 pattients in the non-transformed group, 73 males and 89 females, aged (57±12) years.The incidence of B symptoms in the transformed group [46.2% (6/13) vs 16.7% (27/162), P=0.018], the proportion with a MALT-international prognostic index (IPI) score≥2 point [69.2% (9/13) vs 17.3% (28/162), P<0.001], and lactate dehydrogenase (LDH) levels [227 (194, 262) vs 173 (146, 196) U/L, P<0.001] were all higher than those in the non-transformed group. The mutation rate of gene in the transformed group [84.6% (11/13) vs 45.7% (74/162), P=0.007] and the mutation rate of ≥2 genes [69.2% (9/13) vs 17.3% (28/162), P<0.001] were both higher than those in the non-transformed group. The mutation rates of the NOTCH1 gene [23.1% (3/13) vs 3.7% (6/162), P=0.021], the SOCS1 gene [15.4% (2/13) vs 0, P=0.005], and the KRAS gene [15.4% (2/13) vs 0, P=0.005] were all higher in the transformed group than those in the non-transformed group. Patients with MALT lymphoma who transformed to DLBCL are often accompanied by B symptoms, a higher MALT-IPI score, elevated LDH and multiple gene mutations, and the mutation frequencies of NOTCH1, SOCS1, and KRAS are higher.
proteins
2026-05-01 | C32-21 Unmasking the Swell: Recurrent Acquired Angioedema as a Manifestation of Marginal Zone Lymphoma
Abstract Introduction Acquired angioedema (AAE) due to C1-esterase inhibitor (C1-INH) deficiency is a rare, potentially fatal disorder caused by increased bradykinin activity leading to vascular permeability and submucosal edema. Unlike hereditary angioedema, AAE typically presents later in life, lacks a family history, and is frequently associated with underlying B-cell lymphoproliferative disorders or autoimmune diseases. Among these, splenic marginal zone lymphoma (MZL) is disproportionately represented, highlighting a paraneoplastic link between complement consumption and tumor activity. Because bradykinin-mediated angioedema does not respond to epinephrine, corticosteroids, or antihistamines, recognition and disease-specific management are crucial to avoid airway compromise. Case Description A 65-year-old woman with newly diagnosed splenic MZL presented with her third episode of sudden tongue swelling now accompanied by progressive dysarthria, drooling, and respiratory distress. In the emergency department, she was administered 1g intravenous (IV) Tranexamic acid, 20 mg IV Famotidine, 50 mg IV Diphenhydramine, and 125 mg IV Methylprednisolone without improvement. Worsening edema necessitated emergent endotracheal intubation for impending airway obstruction.In the intensive care unit, she was treated with intravenous corticosteroids, diphenhydramine, famotidine, and received two units of fresh frozen plasma. Complement studies revealed a low C1q level (<2 mg/dL), and markedly reduced C1 esterase inhibitor assay ( 7%), confirming acquired C1-INH deficiency. C4 level was also depressed, and autoimmune serologies were negative. Following stabilization, she self-extubated without rebound swelling and was discharged with hematology follow-up for ongoing lymphoma-directed therapy and referral to Allergy-Immunology. Discussion This case underscores a rare but clinically significant manifestation of AAE in the setting of splenic MZL. Adult-onset, recurrent, non-pruritic angioedema unresponsive to conventional histaminergic therapies should prompt evaluation for bradykinin-mediated etiologies. Diagnostic confirmation relies on complement testing, specifically, low C1q and C1-INH levels with normal C1-INH gene sequence, distinguishing AAE from hereditary forms. Acute management centers on airway protection and targeted therapy such as plasma-derived or recombinant C1-INH, icatibant (a bradykinin B2-receptor antagonist), or ecallantide (a kallikrein inhibitor), when available. FFP remains a pragmatic option in resource-limited settings. Long-term control depends on treating the underlying lymphoproliferative disorder, which can normalize complement levels and prevent recurrence.Heightened clinical awareness of AAE in patients with unexplained angioedema and concurrent B-cell malignancies can prevent morbidity and mortality through timely diagnosis and multidisciplinary management. This abstract is funded by: none
2025-09-17 | Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies
Abstract Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptides (AMPs), evolutionarily conserved effectors of innate immunity, possess selective cytotoxicity against malignant cells by exploiting tumor-specific membrane alterations. We evaluated the antitumor activity of seven natural AMPs, including Antarctic fish-derived trematocines and chionodracine variants, and amphibian temporins, against MZL cell lines (VL51, Karpas1718) and derivatives resistant to BTK, PI3Kδ, or PI3Kα/δ inhibitors. Among them, W-trematocine and temporin L demonstrated potent dose-dependent cytotoxicity with IC 50 values of 5.7-10 μM, maintaining full activity in all resistant models. Other peptides showed moderate activity, while chionodracine-1 was inactive. Notably, W-trematocine displayed minimal toxicity toward non-malignant cells in prior studies, underscoring its selectivity. AMP-mediated killing, driven by membrane disruption and non-apoptotic death pathways, bypassed conventional resistance mechanisms, suggesting therapeutic potential in relapsed/refractory disease. These findings highlight natural AMPs as promising candidates for development in drug-resistant MZL, warranting further optimization and preclinical validation.
2025-07-14 | Effects of a Cancer-Associated Mutation and Multiple Serine Phosphorylation on Poly(ADP-Ribose) Polymerase 2.
Poly [ADP-ribose] polymerase 2 (PARP2) plays a crucial role in DNA repair. A common single-nucleotide polymorphism (SNP) in the PARP2 gene, rs3093921, has been associated with pancreatic cancer and marginal zone lymphoma (MZL). This SNP results in a missense mutation, D235G, in the PARP2 protein. PARP2 is also reported to undergo post-translational modifications (PTMs), particularly phosphorylation at serine residues 226, 232, and 353. The C-terminal region of PARP2 includes the Trp-Gly-Arg (WGR) and ADP-ribosyl transferase (ART) domains, and the helical subdomain (HD). The latter two, spanning residues 220 to 583, comprise the catalytic region of PARP2. The DNA-induced enzymatic activation of PARP2 is regulated by local destabilization of the HD domain. We used molecular dynamics (MD) simulations to investigate the impact of these three PTMs on both the wild-type (WT) and the mutant (D235G) forms of PARP2. Our simulations suggest that, while neither the cancer-associated mutation nor PTMs on their own significantly alter the overall flexibility of residues within the HD domain, they cause notably greater deviations in the backbone structure of the HD domain compared to the WT. In addition, PTMs in the context of the mutation show reduced interactions between the mutation site and other protein regions, likely due to structural stabilization induced by the PTMs. Importantly, PTMs mitigate the structural disruption caused by the mutation, helping the mutant protein retain a WT-like conformation. Additionally, the HD domain contributes to maintaining PARP2 in its inactive state through its connection with the ART domain. However, the D235G mutation weakens this connection. While PTMs alone do not have a significant impact on this connection, the simultaneous presence of both the mutation and PTMs partially alleviates the disruptive effect of the mutation and leads to partial restoration of the connection between the HD and ART domains.
2025-04-21 | Abstract 612: Antimicrobial peptides with antitumor activity against marginal zone lymphoma cell lines resistant to BTK, PI3K, and BCL2 inhibitors
Abstract Background: Antimicrobial peptides (AMPs) are a class of small proteins produced by all living organisms, from prokaryotes to humans. In higher eukaryotes, AMPs contribute to the host's innate immunity, promptly responding against any pathogen. Due to their mechanism of action, represented mainly by their ability to bind and perturb microbial membranes, AMPs are being explored as novel agents against multidrug-resistant bacteria and anti-cancer agents. Natural peptides could be used as a scaffold to design new AMPs with improved effectiveness, stability, and selectivity. Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell lymphoid tumor. Here, we assessed the antitumor activity of seven AMPs in MZL models with acquired resistance to FDA-approved BTK, PI3K, and BCL2 inhibitors. Methods: Established human cell lines derived from MZL (VL51, Karpas1718) and derivatives with secondary resistance to targeted agents obtained by long drug exposure (n.=3 from VL51, n.=1 from Karpas1718 (Arribas et al, Haematologica 2022; Mol Cancer Ther 2024; ENA 2019; ENA 2020) were exposed to increasing concentrations of AMPs or DMSO, as control. Anti-proliferative activity was assessed by MTT assay after 72 hours of exposure. Results: MZL cell lines were exposed to AMPs originating from Antarctic fishes (Chionodraco hamatus, Trematomus bernacchii; trematocines, n.=2; chionodracines, n.=1) and amphibians (temporins, n.=4;). Anti-proliferative activity was observed in parental MZL with two synthetic AMPs: a Trematomus bernacchii - derived trematocine mutant (Della Pelle et al, Antibiotics 2020), with IC50 values of 7.5 μM in VL51 and 10 μM in Karpas1718 and the Rana temporaria - derived Temporin L (Simmaco et al, Eur J Biochem 1996) with IC50 of 8 μM in VL51 and 15 μM in Karpas1718. Notably, the antiproliferative activity was maintained in all the derivative MZL cell lines with resistance to BTK, PI3K, and BCL2 inhibitors. At higher concentrations, also the other trematocine (Karpas1718 models) and all the temporins (VL51 and Karpas1718 models) had anti-proliferative activity (IC50 values 25-50 μM). Conclusions: AMPs derived from Antarctic fishes and amphibians have in vitro anti-tumor activity in cell lines derived from MZL, including models with acquired resistance to BTK, PI3K, and BCL2 inhibitors. AMPs and their synthetic derivatives can provide novel anti-lymphoma agents with mechanisms of action deeply different from currently used drugs. Citation Format: Filippo Spriano, Alberto J. Arribas, Fangwen Zhang, Maria Luisa Mangoni, Francesco Buonocore, Francesco Bertoni. Antimicrobial peptides with antitumor activity against marginal zone lymphoma cell lines resistant to BTK, PI3K, and BCL2 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 612.
2024-06-01 | Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).
7058 Background: Follicular and marginal zone B cell lymphoma (FL; MZL) demonstrate an indolent course with heterogeneous outcomes anda potential for spontaneous remissions indicating immune system intervention. Therapeutic immunization is therefore an attractive approach but new antigens that evoke a strong immune response are needed. EO2463 expands pre-existing memory CD8+ T cells recognizing non-self protein sequences from gut bacteria which cross-react with B cell antigens and can kill HLA-A2 restricted cells (T2) loaded with target peptides. EO2463 includes 4 HLA-A2 synthetically produced epitopes which exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), as well as a the CD4 helper-epitope UCP2 derived from hTERT. EO2463 is being used to drive anti-tumor activity against B cell malignancies. Methods: Patients (pts) with FL and MZL, stage 1-3A, and HLA-A2, are eligible. In the safety lead-in pts with relapsed/refractory (R/R) disease were given EO2463 SC q2 weeks (w) x 4, then q4w, for a max of 12 months; at w7 lenalidomide (20 mg/day for 21/28 days up to 12 cycles) is added (EL), and if no complete remission (CR) at w19, rituximab (375 mg/m 2 IV, q1w x 4, then q4w x 4) is also added (ER 2 ). Doses evaluated: 150 μg and 300μg/peptide. Results: 3 pts received 150 μg/peptide and 6 pts 300 μg/peptide (EO2463 1 pat, EL 2 pts, ER 2 6 pts): 2 MZL, 7 FL pts with median 2 lines (range 1-4) of prior systemic therapy. No related grade ≥3 adverse events were seen with EO2463 monotherapy. Most common related events were grade 1 to 2 local administration site reactions in 5/9 pts. Adverse events during combination treatment were as expected for R 2 . PET-CT on w6 after EO2463 monotherapy suggested clinical activity in 4/9 pts (1 PR, 1 pt size reduction 15%, 1 pt 20% reduced tracer uptake, 1 pt 5/6 target lesions reduced metabolic activity). Overall objective responses (OR) were seen in 6/9 pts (67%; 1 st OR on EO2463 1 pat, EL 4 pts, ER 2 1 pat), with CR in 5/9 (56%) pts; median time to response was 18w (range 8-43w), response ongoing in 5 pts, range 24-76w. Expansion of specific CD8+ T cells against mimic peptides and targeted B cell antigens were detected in all responding pts, incl. 2 pts with no measurable B cells at baseline (prior anti-CD20). Expansion of specific T cells was detected at w5 in 5/6 pts and was maintained as long as currently tested (up to w94, 43w after last EO2463 dose). No decline in expansions were seen after start rituximab. Conclusions: EO2463 (300 μg/peptide) monotherapy, EL, and ER 2 are well tolerated, with encouraging clinical activity with EO2463 monotherapy and with subsequent CR in 5/9 pts on combo. Rapid and durable expansion of specific CD8+ T cells was seen in all responding pts, consistent with the preclinical hypothesis. Additional cohorts investigate EO2463 alone or in combination in newly diagnosed or R/R pts. Results will be reported at the meeting. Clinical trial information: NCT04669171 .
antibodies
2026-09-13 | Primary Extranodal Marginal Zone Lymphoma of the Breast: A Case Report Highlighting the Clinicopathological Paradigm of an Indolent B-Cell Neoplasm
Primary or secondary lymphoma of the breast is an uncommon entity, accounting for less than 0.5% of all breast malignancies and approximately 1-2% of extranodal lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most frequently reported histological subtype. Marginal zone B-cell lymphoma involving the breast is exceedingly rare, particularly in patients with a prior history of DLBCL. The present case describes an unusual occurrence of synchronous second primary lymphoid neoplasm of breast in a patient previously treated for DLBCL, highlighting its diagnostic rarity. The authors report a rare case of a 57-year-old female with a past history of DLBCL, diagnosed two years ago on histopathological examination of excised lymph node over left neck region. Patient received chemoradiotherapy post-diagnosis and had recovered completely. She now presented with bilateral breast lumps and an additional lump in the left axillary region. An initial histopathological diagnosis of Non-Hodgkin’s Lymphoma of breast was made which needed further immunophenotypic characterisation. Immunohistochemistry (IHC) was done which showed strong positivity for CD45, CD19, CD20, PAX5, Bcl2, Ki-67 which confirmed the diagnosis of Marginal Zone B-cell Lymphoma, emphasising diagnostic challenges. Post histopathological diagnosis and immunohistochemistry, patient received targeted therapy along with chemotherapy to which she responded well. The present case is noteworthy because of the uncommon involvement of both breasts and the axillary region in a patient with a prior diagnosis of DLBCL, suggesting potential disease recurrence or extranodal extension.
2026-09-10 | Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.
Mosunetuzumab is highly effective against many B-cell lymphomas, but longitudinal immune changes induced by intermittently dosed CD20×CD3 bispecific antibodies remain incompletely characterized. We performed immune profiling of peripheral blood samples from patients receiving fixed-duration (6 months) subcutaneous mosunetuzumab for previously untreated follicular or marginal zone lymphoma on a phase 2 clinical trial (NCT04792502). Analyses included flow cytometry, cytokine profiling, and RNA-seq of isolated CD8+ T-cells with TCR repertoire inference. Early (at 3 weeks) on-treatment samples showed broad cytokine induction, CD8+ T-cell redistribution with decreased TEMRA cells and increased CD27+CD62L+ transitional effector memory-like cells, increased PD-1 and LAG-3 expression, and induction of CD8+ transcriptional programs consistent with activation, proliferation, exhaustion priming, and SREBF2-regulated cholesterol metabolism. By mid-treatment (at 3 months), activation-associated features contracted toward baseline, with no evidence of phenotypic exhaustion, though with persistent overexpression of LAG3, HAVCR2, and LAYN on RNA-seq, as well as sustained SREBF2 activation. CD8+ T-cell clonality increased at mid-treatment compared with baseline and higher clonality was associated with early clinical complete response. Mosunetuzumab also induced indirect NK-cell activation and expansion, including skewing toward CD56dimCD16bright effector state. HLA-DR upregulation on NK cells correlated with early increases in NK-activating plasma cytokines, and higher NK-cell count at mid-treatment was associated with complete response. Together, these findings define a CD8+ effector-remodeling state on mosunetuzumab therapy, characterized by clonal expansion, selective inhibitory receptor expression, sustained activation of cholesterol biosynthesis, and cytokine-linked engagement of innate immune mechanisms, providing a framework for potential strategies to support T-cell function and enhance bispecific antibody efficacy.
2026-06-29 | CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with limited curative treatment options. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) has recently been implicated in B-cell receptor signaling in MCL. We evaluated CEACAM1 expression by immunohistochemistry across MCL and other mature B-cell neoplasms, including small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). We retrospectively analyzed 164 lymphoma cases, 35 MM cases, and 2 plasmacytomas. CEACAM1 expression was assessed on tissue microarrays by immunohistochemistry and scored using a prespecified dichotomous cutoff. In DLBCL, CEACAM1 status was correlated with cell-of-origin classification and targeted mutational data. CEACAM1 was expressed in 27 of 30 MCL cases (90%), higher than in the other lymphoma subtypes combined (35%; P < .0001). Expression was also seen in SLL (20/30, 67%), MM (23/35, 66%), MZL (8/22, 36%), and DLBCL (19/82, 23%). In DLBCL, expression was more frequent in germinal center B-cell subtype than activated B-cell subtype cases (30% vs 13%; P = .023). Within sequenced DLBCL cases, CEACAM1 expression was associated with BCL2 and TNFRSF14 mutations. In MM, CEACAM1 expression was not significantly associated with recurrent cytogenetic abnormalities, although a nonsignificant trend toward higher expression in t(11;14) cases (75% vs 53%, Fisher exact P = .28). CEACAM1 is frequently expressed in MCL and in subsets of other mature B-cell neoplasms and MM. These findings support further investigation of CEACAM1 as a biologically relevant marker and potential therapeutic target in selected lymphoid malignancies.
2026-05-13 | Beyond Hypersplenism: Splenic Marginal Zone Lymphoma in an Older Adult with Hemoglobin E/Beta-Thalassemia.
With improvements in blood safety and availability, along with broad access to safe and effective iron chelation, outcomes for patients with thalassemia have greatly improved over recent decades. Previously a predominantly pediatric condition, thalassemia is now increasingly encountered in an aging population. We describe an adult man with HbE/β-thalassemia whose course was complicated by progressive splenomegaly and cytopenias, initially attributed to his underlying thalassemia. Further evaluation, however, revealed splenic marginal zone lymphoma. After the initiation of anti-B-cell therapy, he experienced rapid clinical improvement and was able to avoid surgical splenectomy. This case highlights how complications ascribed to thalassemia can overlap with other diagnoses that may become more prevalent with age, and demonstrates the importance of maintaining a broad differential when symptoms progress despite appropriate thalassemia-directed management.
2026-05-11 | Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report.
Marginal zone lymphomas (MZL) are indolent lymphomas that may undergo transformation into aggressive lymphomas, most frequently diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (LONCA) is an antibody-drug conjugate used in the treatment of relapsed/refractory large B-cell lymphomas. Here we present the clinical case of a patient with nodal transformed DLBCL and concomitant bone marrow involvement by indolent lymphoma successfully treated with LONCA. However the therapy was discontinued after six cycles as the patient developed treatment-related bone marrow aplasia. This case raises concerns about prolonged hematologic toxicity of LONCA, particularly in patients with pre-existing marrow involvement while highlights the potential of this drug to induce deep and durable response, even after limited exposure.
other
2026-09-24 | Longitudinal single-cell and spatial transcriptomics reveals intratumor heterogeneity, therapeutic response, and comparative value of canine marginal zone lymphoma.
Diffuse B-cell lymphomas are the most prevalent canine hematologic malignancies, and their clinical presentation resembles that of human B-cell non-Hodgkin lymphomas (NHLs). However, a lack of a clear subtyping framework perpetuates imprecise treatment approaches that fail to address mechanisms of therapy resistance. Here, we employed deep phenotyping via serial sampling and longitudinal transcriptomics to evaluate intratumoral composition and therapy response in a 6-year-old neutered male goldendoodle with stage 5A marginal zone lymphoma (MZL). Following sequential treatment consisting of a single IV dose of oncolytic vesicular stomatitis virotherapy (VSV) and standard CHOP chemotherapy 30 days later, we performed scRNAseq on seven serial lymph node biopsies and spatial sequencing on a resection taken 10 days post-VSV treatment. B cells (>90%) comprised three transcriptionally distinct and temporally stable subpopulations, with specific copy number profiles and robust spatial organization despite disrupted lymph node architecture. Analysis across subpopulations revealed downregulation of the quiescence program including KLF2, suggesting similarity to KLF2-deficient human MZL. While VSV successfully reached target B cells, downstream transcriptional responses were predominantly localized to the T-cell compartment. T cells (≤6%) showed increased proliferation and upregulation of cytotoxicity markers post-VSV administration, enriching for leukocyte-mediated cytotoxicity pathways consistent with an anti-viral immune response. Ultimately, these results provide an in vivo proof-of-concept for the treatment paradigm in canine lymphoma, while emphasizing the need for improved subtyping frameworks and multidimensional treatment strategies targeting intratumoral heterogeneity.
2026-04-13 | Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma
Marginal zone lymphoma (MZL) is an indolent subtype of non-Hodgkin lymphoma with heterogeneous clinical features. First-line treatment typically involves anti-CD20 monoclonal antibodies with or without chemotherapy. Although Bruton’s tyrosine kinase (BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R) MZL, their role as first-line therapy remains unclear. This single-center retrospective study included 25 treatment-naïve patients with MZL who received orelabrutinib (150 mg once daily) plus either rituximab or obinutuzumab for 6 cycles, followed by orelabrutinib maintenance for up to 6 months. The primary endpoint was overall response rate (ORR), assessed according to the 2014 Lugano criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. The ORR was 96.0%, comprising 12 complete response (CR) and 12 partial response (PR), with 1 case of stable disease (SD). Among the 13 patients with ocular adnexal MZL (OAML), 5 achieved CR, and 8 achieved PR. In the rituximab subgroup (n = 10), 5 patients achieved CR and 5 achieved PR, whereas in the obinutuzumab subgroup (n = 15), 7 achieved CR, 7 achieved PR, and 1 had SD; there was no significant difference in CR rate between the 2 groups (50.0% vs 46.7%, p = 1.000). Treatment-related adverse events (AEs) occurred in 32.0% of patients, with neutropenia (20.0%) and thrombocytopenia (12.0%) being the most common. Grade 3 to 4 events occurred in 12.0% of patients, with no significant differences in safety profiles between the rituximab and obinutuzumab subgroups. In conclusion, CD20 monoclonal antibodies combined with orelabrutinib may represent a feasible, low-toxicity first-line option for MZL, with favorable short-term efficacy and tolerability observed in this cohort. These preliminary findings warrant confirmation in larger prospective randomized studies to establish long-term benefits and safety.
2026-04-03 | Primary esophageal marginal zone lymphoma with respiratory symptoms: a case report and review of the literature.
Primary esophageal lymphoma is a rare disease whose pathogenesis may be related to immune abnormalities. We report a case of primary esophageal marginal zone lymphoma (MZL) in the esophagus for 2 years, which initially presented with respiratory symptoms and was subsequently diagnosed by endoscopic ultrasound-guided fine-needle aspiration. A 68-year-old male presented with a 10-day history of cough, excessive sputum production, and wheezing after physical activity. Two years prior to this admission, the patient had sought medical attention at our hospital for fever and cough. After completing the relevant examinations, the preliminary diagnosis was considered to be a pulmonary infection, with the possibility of an esophageal neoplastic lesion. Upon readmission, a follow-up chest CT revealed thickening of the esophageal wall in multiple segments, which was more pronounced than it had been 2 years previously, and tracheal compression. Upper gastrointestinal endoscopy revealed a widespread, protruding lesion along the entire esophagus, with a smooth mucosal surface and no ulceration. Endoscopic ultrasound revealed the disappearance of the normal layered structure of the esophageal wall at the site of the lesion. PET-CT demonstrated uneven increased radioactive uptake throughout the esophagus. Bone marrow aspiration did not reveal any tumor involvement. Histopathological and immunohistochemical examinations revealed marginal zone lymphoma. Primary esophageal lymphoma has significant clinical heterogeneity, typically starting with progressive dysphagia and weight loss. This patient has a long history of atypical symptoms, representing the first case to present with respiratory symptoms without dysphagia. Due to the extremely low incidence of primary esophageal lymphoma and the lack of typical symptoms, imaging findings, and endoscopic manifestations, it is prone to misdiagnosis. Differential diagnosis is necessary to distinguish it from esophageal malignancies such as esophageal squamous cell carcinoma and esophageal adenocarcinoma, as well as benign esophageal conditions like esophagitis and esophageal tuberculosis. Performing endoscopic ultrasound-guided fine needle aspiration to complete pathological biopsy is crucial to reduce the risk of misdiagnosis and facilitate early diagnosis. Currently, after two courses of the G-CVP regimen (Obinutuzumab + Cyclophosphamide + Vincristine + Prednisone) demonstrated suboptimal efficacy, the treatment was switched to a triple combination of Obinutuzumab, Orelabrutinib, and Lenalidomide, which has now completed six courses.
2026-01-19 | Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib-rituximab.
Marginal zone lymphoma is the second most common subtype of indolent non-Hodgkin lymphoma. Its clinical manifestations are heterogeneous and largely determined by the involved site. Chylous ascites, as the initial presentation of marginal zone lymphoma, is extremely rare. We report a 79-year-old man who presented with rapidly progressive abdominal distension due to high-volume chylous ascites. Flow cytometry of the ascitic fluid revealed a monoclonal lambda-restricted B-cell population consistent with low-grade B-cell lymphoma. Bone marrow biopsy confirmed splenic marginal zone lymphoma. Initial rituximab monotherapy was ineffective; however, combination therapy with orelabrutinib and rituximab led to complete resolution of ascites after two cycles and marked disease control. At 6-month follow-up, the patient remained in remission. Clinicians should consider lymphoma in the differential diagnosis of unexplained chylous ascites. Prompt etiologic treatment can result in favorable outcomes even in elderly patients with advanced disease.
2025-11-03 | Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study
Abstract Background: Emerging evidence suggests that triple-combination regimens incorporating Bruton tyrosine kinase (BTK) inhibitors, CD20-targeted agents, and immunomodulatory drugs (e.g., lenalidomide) may exhibit promising antitumor activity in indolent B-cell non-Hodgkin lymphomas (B-NHLs). In this study, we evaluated the efficacy and safety of orelabrutinib plus obinutuzumab and lenalidomide(GOL regimen) as a first-line therapy for MZL patients, aiming to assess its potential as a chemotherapy-free treatment option. Methods: In this prospective single-arm multicenter phase II trial (NCT06454968), eligible treatment-naïve adults (≥18 years) with histologically confirmed marginal zone lymphoma requiring systemic therapy received six 21-day cycles of induction therapy (oral orelabrutinib 150 mg QD on days 1-21, intravenous obinutuzumab 1000 mg on day 1 of each cycle, and oral lenalidomide 25 mg QD on days 1-14) followed by six 28-day cycles of orelabrutinib monotherapy (150 mg QD). The primary endpoint of our study is complete response rate, secondary endpoints were overall response rate, duration of response, uMRD rate of SMZL by IgH-DNA sequencing, and safety. Results: As of August 1, 2025, a total of 23 patients were enrolled in the study. The median age was 60 years (range: 36-81) with a male-to-female ratio of 0.92:1. Subtype distribution included: MALT/EMZL (n=9, 39.1%), SMZL (n=9, 39.1%), and dissMZL (n=5, 21.8%). All patients had Ann Arbor stage IV disease, with 6 cases (26.1%) presenting B symptoms. The MZL-IPI score distribution was: 0 points in 6 cases (26.1%), 1-2 points in 14 cases (60.9%), and 3-5 points in 3 cases (13.0%). Monoclonal gammopathy was observed in 9 out of 19 evaluable patients. All splenic marginal zone lymphoma (SMZL) patients exhibited massive splenomegaly, with 4 out of 9 showing baseline leukocytosis (peak WBC count 387.5×10⁹/L, lymphocyte count 371.9×10⁹/L). To date, 10 patients have completed 6 cycles of the three-drug combination (GOL) regimen, while 5 patients have completed all treatment and entered the follow-up phase. Among 18 response-evaluable patients, the overall response rate (ORR) was 88.9% (16/18) and the complete response rate (CRR) was 72.2% (13/18). By subtype analysis:SMZL patients demonstrated excellent outcomes with 100% ORR (6/6) and 100% CRR (6/6), all achieving complete remission by cycle 3, including 5 cases (83.3%) attaining MRD negativity by IgH-DNA sequencing;MALT/EMZL patients showed 77.8% ORR (7/9) and 66.7% CRR (6/9);dissMZL patients achieved 100% ORR (3/3) but a lower CRR of 33.3% (1/3). With a median follow-up of 8.1 months (range 2.3-13.1 months), none of the responding patients experienced disease progression, and the median duration of response (DOR) has not been reached. Regarding safety, all-grade adverse events included: infusion-related reactions (6/23), thrombocytopenia (6/23), rash (5/23), herpes zoster (2/23), petechiae (2/23), leukopenia (1/23), influenza A pneumonia (1/23), and invasive pulmonary aspergillosis (1/23). Grade 3 adverse events were limited to infusion-related reactions (2/23), thrombocytopenia (2/23), and rash (2/23), with no grade 4-5 adverse events reported. Conclusion: This phase II study demonstrates that the novel triple-combination regimen shows promising efficacy in treatment-naïve MZL patients, with an impressive overall response rate (88.9%) and complete response rate (72.2%), particularly in SMZL patients who achieved 100% CR. The regimen exhibited a manageable safety profile with no grade 4-5 adverse events. Early MRD negativity in SMZL suggests potential for durable remissions. These results support further study of this chemotherapy-free approach.
small molecules
2026-09-25 | Choroidal Involvement in Nodal Marginal Zone Lymphoma Presenting as Serous Retinal Detachment.
To describe the clinical presentation and multimodal imaging findings of choroidal involvement in nodal marginal zone lymphoma (NMZL) presenting as serous retinal detachment and its response to systemic chemotherapy. Retrospective review of clinical records and multimodal imaging findings, with joint interpretation by a uveitis specialist and the hematology-oncology team. A 63-year-old woman presented with decreased vision in the left eye and was found to have a shallow serous retinal detachment. Inflammatory choroiditis was initially suspected and systemic corticosteroids therapy was initiated, resulting in transient improvement. Subsequent examination revealed recurrent subretinal fluid with multiple subretinal yellow infiltrates and diffuse choroidal thickening after the steroid effect subsided. Optical coherence tomography demonstrated undulating retinal pigment epithelium. Choroidal lymphoma was considered, prompting thorough systemic investigation. Systemic imaging later identified axillary and intra-abdominal lymphadenopathy and a right breast mass. Histopathology of the breast lesion confirmed NMZL. The patient was treated with rituximab-based systemic chemotherapy with intrathecal chemotherapy, achieving partial systemic response and complete ocular remission. Choroidal involvement in NMZL is rare and may present as steroid-responsive but recurrent serous retinal detachment, mimicking inflammatory disease. Systemic evaluation with biopsy of accessible extraocular sites, in conjunction with compatible ocular findings, can establish the diagnosis while avoiding high-risk choroidal biopsy. Early recognition and multidisciplinary collaboration are essential to enable timely diagnosis and systemic treatment.
2026-09-06 | First-line therapy and maintenance outcomes in Chinese patients with marginal zone lymphoma: a multicenter retrospective analysis with prognostic implications for chemotherapy decision-making.
This multicenter retrospective study evaluated first-line treatment patterns, maintenance therapy outcomes, and prognostic factors in 171 newly diagnosed marginal zone lymphoma (MZL) patients treated across multiple centers in Fujian Province, China (2019-2024). The MALT subtype predominated (79.0%), with the gastrointestinal tract and lung being the most common primary sites. The first-line overall response rate was 91.1%, with 67.3% of patients achieving complete remission. Five-year progression-free survival (PFS) and overall survival (OS) were 82.6% and 94.7%, respectively. Maintenance therapy, received by 66.1% of patients, was associated with superior 5-year OS (100% vs. 87.5%, P=0.0104). Multivariate analysis identified Ki-67 >20% (HR=3.208, P=0.024) and high tumor burden (HR=4.670, P=0.003) as independent negative predictors for PFS, while high tumor burden (HR=4.493, P=0.004) and B symptoms (HR=3.324, P=0.030) predicted worse OS. Chinese MZL patients demonstrated favorable outcomes, and maintenance therapy conferred a significant OS benefit. Ki-67, tumor burden, and B symptoms serve as practical prognostic indicators to inform risk stratification and personalized treatment planning.
2026-09-03 | BRAF V600E-mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia.
To establish the occurrence of BRAF mutation in marginal zone lymphomas (MZLs) and study its impact on clinical presentation, pathologic features, and disease classification. Conventional histology, immunohistochemistry, flow cytometry, and molecular methods were used. We identified 2 BRAF‑mutated MZL cases: a nodal MZL (NMZL) with BRAF V600E and partial morphologic/immunophenotypic overlap with hairy cell leukemia (HCL) and an extranodal MZL with a non-V600E BRAF mutation co‑occurring with TET2, KRAS, and TP53 variants. The NMZL case showed strong CD25 and CD123 expression and patchy cyclin D1 expression; together with the presence of a BRAF V600E mutation, these features overlapped with HCL. However, the absence of annexin A1 and CD103 expression, along with the remaining morphologic features in the lymph node, supported accurate classification as NMZL. These 2 cases expand the mutational spectrum of MZL and illustrate important diagnostic pitfalls. These observations underscore that BRAF V600E, while highly specific and clinically useful for HCL in the context of a B‑cell lymphoproliferative process involving blood and marrow, is not entirely pathognomonic and must be interpreted alongside morphology and a full immunophenotypic panel. Integrating BRAF testing into the workup of challenging small B‑cell lymphomas may refine diagnosis and reveal rare, potentially targetable MAPK pathway lesions.
2026-08-25 | Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma.
There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase II MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R/R MZL treated with zanubrutinib after at least one prior anti-CD20-based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), MALT (18.9%), nodal (19.8%), and non-classifiable (6%). The median number of prior lines of therapy (LoT) was 1.5 (range 1-7); 26% were refractory to the immediately preceding line, and 59% were POD24 to frontline. Thirty-one patients (26.3%) would not have met MAGNOLIA eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA eligibility. Fewer prior LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than cases with progressing disease (p < 0.01). Adverse events (AEs) were reported in 34.1% of patients (grade ≥ 3 in 14.4%). MAGNOLIA-ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (p = 0.04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R/R MZL, with improved outcomes when administered earlier in the disease.
2026-08-02 | NLRC5-Deficient Macrophages Promote a Tumor-Permissive Phenotype via AXL- and MERTK-Mediated Efferocytosis.
The innate immune protein NLRC5 plays a key role in cancer immune surveillance. Reduced NLRC5 expression is associated with a poor prognosis for many types of cancers. Previously, we showed that mice with a myeloid-specific deletion of Nlrc5 (Nlrc5mø-KO) develop gastric lymphoid lesions to Helicobacter infection resembling early-stage marginal zone lymphoma. We hypothesized that NLRC5 deficiency may promote a tumor-permissive microenvironment mediated by tumor-associated macrophages (TAMs). Consistent with this hypothesis, splenic macrophages from Helicobacter-infected Nlrc5mø-KO mice had upregulated expression of genes encoding the TAM receptor tyrosine kinases, Axl and Mertk. The levels of AXL and MERTK gene expression and MERTK phosphorylation were increased in NLRC5-/- THP-1 macrophages when compared with WT cells. In response to Helicobacter stimulation, Nlrc5-/- macrophages had significantly elevated anti-inflammatory responses (IL-10, TGF-β, Socs1, Socs3) compared with WT cells. Importantly, Nlrc5-/-macrophages showed enhanced efferocytosis and reduced antigen presentation to CD8+ T cells. Pretreatment of macrophages with AXL and MERTK inhibitors (R428, UNC2025) resulted in reduced efferocytosis and phosphorylation of downstream signaling molecules, STAT3 and ERK1/2. We propose that defective NLRC5 signaling in macrophages leads to tumor-permissive responses, thereby promoting the development of gastric lymphoid neogenesis to Helicobacter infection.
cell therapies
2026-08-31 | Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.
While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL. The primary end-point was progression-free survival from first relapse (2PFS), with survival after relapse (SAR) as the secondary end-point. The median 2PFS was 24 months, with a 2-year 2PFS rate of 49% and a 2-year SAR rate of 66%. Multivariable analysis identified advanced age, progression of disease within 24 months (POD24) and high MZL International Prognostic Index (MZL-IPI) scores as significant predictors of inferior survival. Patients with splenic and disseminated subtypes also demonstrated worse outcomes. Relapse following systemic therapy often marks a transition to an aggressive clinical course. Time to progression and the MZL-IPI are robust tools for risk stratification, highlighting an urgent need for novel therapeutic strategies for high-risk relapsed MZL populations.
2026-08-28 | CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell non-Hodgkin lymphoma, but centralised manufacturing-with its complex logistics and long vein-to-vein times-drives up costs and restricts access. We aimed to evaluate the safety of GLPG5101, a fresh, CD19 CAR T-cell product manufactured through a decentralised process, and determine the recommended phase 2 dose. This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study, was executed in five hospitals in the Netherlands and Belgium. Patients aged 18 years or older, with histologically confirmed diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) after two or more lines of therapy, measurable disease according to the Lugano classification, Eastern Cooperative Oncology Group Performance Status 0-2, and adequate organ function were enrolled. Patients were treated with a single intravenous infusion at one of three dose levels of GLPG5101 (dose level 1 [35-50 × 106 viable CAR+ T-cells], dose level 2 [85-110 × 106 viable CAR+ T-cells], and dose level 3 [200-250 × 106 viable CAR+ T-cells]). The phase 1 part of the study applied a Bayesian Optimal Interval design and the primary endpoints were safety (incidence of adverse events and serious adverse events until end of treatment [week 14], and dose-limiting toxicities [DLTs] until day 28) in patients who received fresh GLPG5101 at any dose (excluding recipients of non-conforming product [not meeting prespecified release criteria other than dose]) and determination of the recommended phase 2 dose. The study was registered with ClinicalTrials.gov (NCT06561425) and is closed for recruitment. From March 15, 2022, to Sept 10, 2024, 27 patients were screened for eligibility, 24 of whom were enrolled, underwent leukapheresis and lymphodepleting chemotherapy and received GLPG5101. Data cutoff was June 1, 2025. In the intention-to-treat population (n=24), the median age was 66·5 years (IQR 59·0-71·5), 15 (63%) patients were male, nine (38%) were female, and 21 (88%) were White. One of the 24 patients received a non-conforming product and was excluded from the safety analysis population. Median follow-up was 24·0 months (IQR 20·7-24·9). Five DLTs were reported: grade 3 thrombocytopenia (n=1, dose level 1), death from intra-abdominal haemorrhage (n=1, dose level 2), and grade 4 prolonged neutropenia not resolving to grade 2 or lower within 28 days (n=1 at dose level 1 and n=2 at dose level 2). All 23 patients in the safety analysis population had grade 3 or higher treatment-emergent adverse events; the most common were neutropenia (22 [96%]), leukopenia (nine [39%]), lymphopenia (seven [30%]), anaemia (six [26%]), and thrombocytopenia (five [22%]). Treatment-related deaths occurred in four patients: one during the 14-week treatment period due to intra-abdominal haemorrhage, and three after the treatment period due to Escherichia coli sepsis (n=1), immune-effector cell-associated haemophagocytic lymphohistiocytic syndrome (n=1), and COVID-19 (n=1). The safety review committee selected 110 × 106 (range 50-110 × 106) viable CAR T-cells as the recommended phase 2 dose. The results of this study showed the feasibility of rapid multicentre decentralised manufacturing and delivery of fresh CAR T-cell therapy in heavily pretreated B-cell non-Hodgkin lymphoma. The phase 2 part of ATALANTA-1 will provide further information on clinical activity and safety. CellPoint, Lakefront Biotherapeutics.
2026-08-05 | A 13-Year Review of Non-Diffuse Large B Cell Lymphomas of the Central Nervous System at a Tertiary Hospital: A Case Series Study.
Non-diffuse large B-cell lymphomas (non-DLBCL) of the central nervous system (CNS) are rare and diagnostically challenging. This study aims to characterize the clinical, radiological, and pathological features of non-DLBCL CNS lymphomas diagnosed at a tertiary care center over 13 years, highlighting diagnostic pitfalls. A retrospective review was conducted of non-DLBCL CNS lymphoma cases diagnosed at Sunnybrook Health Sciences Centre, Toronto, from 2010 to 2022. Clinical, demographic, and radiological data were extracted from medical records. Imaging was reviewed by a neuroradiologist, and histopathological slides and molecular data were re-evaluated by a pathology team. Additional tests were performed to update classifications per the 5th edition of the WHO Classification of Haematolymphoid Tumors. Seventeen cases were identified (11 males, 6 females; age 38-76), compared to 72 DLBCL cases during the same period. Nine cases were extra-axial and eight intra-axial. Eight were primary and nine secondary CNS lymphomas. B-cell lymphomas (n = 13) included extra-nodal marginal zone lymphoma (n = 6), follicular lymphoma, mantle cell lymphoma, CLL, intravascular large B-cell lymphoma (n = 2), EBV+ LBCL, and polymorphic PTLD. T-cell lymphomas (n = 4) included PTCL, NOS (n = 2), ALK-negative ALCL, and secondary mycosis fungoides. Imaging revealed four major patterns, and symptoms were largely due to mass effect. This case series emphasizes the considerable heterogeneity of non-DLBCL CNS lymphomas and the diagnostic challenges they present. It highlights key features that can aid recognition and improve diagnostic accuracy for these rare CNS entities. Trial Registration: SUN-5771.
2026-05-27 | Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy with notable genetic, epigenetic, and clinical heterogeneity. This study utilized coding and non-coding sequencing (n=74), including whole-genome sequencing (WGS) on 24 paired tumour-normal samples, targeted sequencing (n=55) and DNA methylation in 126 cases to characterize the disease. From WGS, we identified recurrent, predominantly clonal, coding mutations in KLF2 (50%), KMT2D (25%) and NOTCH2 (25%), alongside rare mutations in FLNC (8%), novel mutations in FAM135B (17%) and non-coding mutational hotspots in BCL6, PAX5 and BACH2, linked to aberrant somatic hypermutation. At least one non-coding hotspot was detected in 69% of cases. Copy-number aberrations (CNAs) were present in 73% of cases, including del(7q) (27%), gain(3q) (17%) and trisomy 12 (13%). DNA methylation profiling revealed two epigenetic subgroups: SMZL-HR (high-risk, n=67) and SMZL-LR (low-risk, n=59). SMZL-HR was associated with adverse features such as female sex, IGHV1-2*04 usage, KLF2 mutations, del(7q), shorter telomeres, and elevated epiCMIT scores. Transcriptomic analysis highlighted enhanced cell proliferation in SMZL-HR, with enrichment of E2F and G2M checkpoint pathways and epigenetic regulation via EZH2. SMZL-HR patients had significantly shorter time to first treatment (TTFT) (HR: 1.9, p=.003) and reduced overall survival (HR: 2.5, p=.039): 85% of SMZL-HR patients required treatment and showed a higher frequency of transformation (p=.007) and mortality (p<.001). Multivariate analysis confirmed SMZL-HR as an independent predictor of shorter TTFT (HR: 2.4, p=.001). These findings demonstrate the role of DNA methylation and molecular profiling in SMZL risk stratification.
2026-05-08 | [Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma].
To analyze the clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue (MALT) lymphoma transformed into diffuse large B-cell lymphoma (DLBCL). A retrospective analysis was performed on patients diagnosed with MALT lymphoma at Henan Provincial People's Hospital from January 2016 to December 2025. According to whether DLBCL transformation occurred, the patients were divided into the transformed group (MALT lymphoma patients who developed DLBCL transformation) and the non-transformed group. The patients were followed up until December 30, 2025, and the clinical and genetic characteristics were compared between the two groups. A total of 175 patients were included, including 13 patients in the transformation group, 4 males and 9 females, aged (58±18) years; and 162 pattients in the non-transformed group, 73 males and 89 females, aged (57±12) years.The incidence of B symptoms in the transformed group [46.2% (6/13) vs 16.7% (27/162), P=0.018], the proportion with a MALT-international prognostic index (IPI) score≥2 point [69.2% (9/13) vs 17.3% (28/162), P<0.001], and lactate dehydrogenase (LDH) levels [227 (194, 262) vs 173 (146, 196) U/L, P<0.001] were all higher than those in the non-transformed group. The mutation rate of gene in the transformed group [84.6% (11/13) vs 45.7% (74/162), P=0.007] and the mutation rate of ≥2 genes [69.2% (9/13) vs 17.3% (28/162), P<0.001] were both higher than those in the non-transformed group. The mutation rates of the NOTCH1 gene [23.1% (3/13) vs 3.7% (6/162), P=0.021], the SOCS1 gene [15.4% (2/13) vs 0, P=0.005], and the KRAS gene [15.4% (2/13) vs 0, P=0.005] were all higher in the transformed group than those in the non-transformed group. Patients with MALT lymphoma who transformed to DLBCL are often accompanied by B symptoms, a higher MALT-IPI score, elevated LDH and multiple gene mutations, and the mutation frequencies of NOTCH1, SOCS1, and KRAS are higher.
proteins
2026-05-01 | C32-21 Unmasking the Swell: Recurrent Acquired Angioedema as a Manifestation of Marginal Zone Lymphoma
Abstract Introduction Acquired angioedema (AAE) due to C1-esterase inhibitor (C1-INH) deficiency is a rare, potentially fatal disorder caused by increased bradykinin activity leading to vascular permeability and submucosal edema. Unlike hereditary angioedema, AAE typically presents later in life, lacks a family history, and is frequently associated with underlying B-cell lymphoproliferative disorders or autoimmune diseases. Among these, splenic marginal zone lymphoma (MZL) is disproportionately represented, highlighting a paraneoplastic link between complement consumption and tumor activity. Because bradykinin-mediated angioedema does not respond to epinephrine, corticosteroids, or antihistamines, recognition and disease-specific management are crucial to avoid airway compromise. Case Description A 65-year-old woman with newly diagnosed splenic MZL presented with her third episode of sudden tongue swelling now accompanied by progressive dysarthria, drooling, and respiratory distress. In the emergency department, she was administered 1g intravenous (IV) Tranexamic acid, 20 mg IV Famotidine, 50 mg IV Diphenhydramine, and 125 mg IV Methylprednisolone without improvement. Worsening edema necessitated emergent endotracheal intubation for impending airway obstruction.In the intensive care unit, she was treated with intravenous corticosteroids, diphenhydramine, famotidine, and received two units of fresh frozen plasma. Complement studies revealed a low C1q level (<2 mg/dL), and markedly reduced C1 esterase inhibitor assay ( 7%), confirming acquired C1-INH deficiency. C4 level was also depressed, and autoimmune serologies were negative. Following stabilization, she self-extubated without rebound swelling and was discharged with hematology follow-up for ongoing lymphoma-directed therapy and referral to Allergy-Immunology. Discussion This case underscores a rare but clinically significant manifestation of AAE in the setting of splenic MZL. Adult-onset, recurrent, non-pruritic angioedema unresponsive to conventional histaminergic therapies should prompt evaluation for bradykinin-mediated etiologies. Diagnostic confirmation relies on complement testing, specifically, low C1q and C1-INH levels with normal C1-INH gene sequence, distinguishing AAE from hereditary forms. Acute management centers on airway protection and targeted therapy such as plasma-derived or recombinant C1-INH, icatibant (a bradykinin B2-receptor antagonist), or ecallantide (a kallikrein inhibitor), when available. FFP remains a pragmatic option in resource-limited settings. Long-term control depends on treating the underlying lymphoproliferative disorder, which can normalize complement levels and prevent recurrence.Heightened clinical awareness of AAE in patients with unexplained angioedema and concurrent B-cell malignancies can prevent morbidity and mortality through timely diagnosis and multidisciplinary management. This abstract is funded by: none
2025-09-17 | Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies
Abstract Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptides (AMPs), evolutionarily conserved effectors of innate immunity, possess selective cytotoxicity against malignant cells by exploiting tumor-specific membrane alterations. We evaluated the antitumor activity of seven natural AMPs, including Antarctic fish-derived trematocines and chionodracine variants, and amphibian temporins, against MZL cell lines (VL51, Karpas1718) and derivatives resistant to BTK, PI3Kδ, or PI3Kα/δ inhibitors. Among them, W-trematocine and temporin L demonstrated potent dose-dependent cytotoxicity with IC 50 values of 5.7-10 μM, maintaining full activity in all resistant models. Other peptides showed moderate activity, while chionodracine-1 was inactive. Notably, W-trematocine displayed minimal toxicity toward non-malignant cells in prior studies, underscoring its selectivity. AMP-mediated killing, driven by membrane disruption and non-apoptotic death pathways, bypassed conventional resistance mechanisms, suggesting therapeutic potential in relapsed/refractory disease. These findings highlight natural AMPs as promising candidates for development in drug-resistant MZL, warranting further optimization and preclinical validation.
2025-07-14 | Effects of a Cancer-Associated Mutation and Multiple Serine Phosphorylation on Poly(ADP-Ribose) Polymerase 2.
Poly [ADP-ribose] polymerase 2 (PARP2) plays a crucial role in DNA repair. A common single-nucleotide polymorphism (SNP) in the PARP2 gene, rs3093921, has been associated with pancreatic cancer and marginal zone lymphoma (MZL). This SNP results in a missense mutation, D235G, in the PARP2 protein. PARP2 is also reported to undergo post-translational modifications (PTMs), particularly phosphorylation at serine residues 226, 232, and 353. The C-terminal region of PARP2 includes the Trp-Gly-Arg (WGR) and ADP-ribosyl transferase (ART) domains, and the helical subdomain (HD). The latter two, spanning residues 220 to 583, comprise the catalytic region of PARP2. The DNA-induced enzymatic activation of PARP2 is regulated by local destabilization of the HD domain. We used molecular dynamics (MD) simulations to investigate the impact of these three PTMs on both the wild-type (WT) and the mutant (D235G) forms of PARP2. Our simulations suggest that, while neither the cancer-associated mutation nor PTMs on their own significantly alter the overall flexibility of residues within the HD domain, they cause notably greater deviations in the backbone structure of the HD domain compared to the WT. In addition, PTMs in the context of the mutation show reduced interactions between the mutation site and other protein regions, likely due to structural stabilization induced by the PTMs. Importantly, PTMs mitigate the structural disruption caused by the mutation, helping the mutant protein retain a WT-like conformation. Additionally, the HD domain contributes to maintaining PARP2 in its inactive state through its connection with the ART domain. However, the D235G mutation weakens this connection. While PTMs alone do not have a significant impact on this connection, the simultaneous presence of both the mutation and PTMs partially alleviates the disruptive effect of the mutation and leads to partial restoration of the connection between the HD and ART domains.
2025-04-21 | Abstract 612: Antimicrobial peptides with antitumor activity against marginal zone lymphoma cell lines resistant to BTK, PI3K, and BCL2 inhibitors
Abstract Background: Antimicrobial peptides (AMPs) are a class of small proteins produced by all living organisms, from prokaryotes to humans. In higher eukaryotes, AMPs contribute to the host's innate immunity, promptly responding against any pathogen. Due to their mechanism of action, represented mainly by their ability to bind and perturb microbial membranes, AMPs are being explored as novel agents against multidrug-resistant bacteria and anti-cancer agents. Natural peptides could be used as a scaffold to design new AMPs with improved effectiveness, stability, and selectivity. Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell lymphoid tumor. Here, we assessed the antitumor activity of seven AMPs in MZL models with acquired resistance to FDA-approved BTK, PI3K, and BCL2 inhibitors. Methods: Established human cell lines derived from MZL (VL51, Karpas1718) and derivatives with secondary resistance to targeted agents obtained by long drug exposure (n.=3 from VL51, n.=1 from Karpas1718 (Arribas et al, Haematologica 2022; Mol Cancer Ther 2024; ENA 2019; ENA 2020) were exposed to increasing concentrations of AMPs or DMSO, as control. Anti-proliferative activity was assessed by MTT assay after 72 hours of exposure. Results: MZL cell lines were exposed to AMPs originating from Antarctic fishes (Chionodraco hamatus, Trematomus bernacchii; trematocines, n.=2; chionodracines, n.=1) and amphibians (temporins, n.=4;). Anti-proliferative activity was observed in parental MZL with two synthetic AMPs: a Trematomus bernacchii - derived trematocine mutant (Della Pelle et al, Antibiotics 2020), with IC50 values of 7.5 μM in VL51 and 10 μM in Karpas1718 and the Rana temporaria - derived Temporin L (Simmaco et al, Eur J Biochem 1996) with IC50 of 8 μM in VL51 and 15 μM in Karpas1718. Notably, the antiproliferative activity was maintained in all the derivative MZL cell lines with resistance to BTK, PI3K, and BCL2 inhibitors. At higher concentrations, also the other trematocine (Karpas1718 models) and all the temporins (VL51 and Karpas1718 models) had anti-proliferative activity (IC50 values 25-50 μM). Conclusions: AMPs derived from Antarctic fishes and amphibians have in vitro anti-tumor activity in cell lines derived from MZL, including models with acquired resistance to BTK, PI3K, and BCL2 inhibitors. AMPs and their synthetic derivatives can provide novel anti-lymphoma agents with mechanisms of action deeply different from currently used drugs. Citation Format: Filippo Spriano, Alberto J. Arribas, Fangwen Zhang, Maria Luisa Mangoni, Francesco Buonocore, Francesco Bertoni. Antimicrobial peptides with antitumor activity against marginal zone lymphoma cell lines resistant to BTK, PI3K, and BCL2 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 612.
2024-06-01 | Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).
7058 Background: Follicular and marginal zone B cell lymphoma (FL; MZL) demonstrate an indolent course with heterogeneous outcomes anda potential for spontaneous remissions indicating immune system intervention. Therapeutic immunization is therefore an attractive approach but new antigens that evoke a strong immune response are needed. EO2463 expands pre-existing memory CD8+ T cells recognizing non-self protein sequences from gut bacteria which cross-react with B cell antigens and can kill HLA-A2 restricted cells (T2) loaded with target peptides. EO2463 includes 4 HLA-A2 synthetically produced epitopes which exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), as well as a the CD4 helper-epitope UCP2 derived from hTERT. EO2463 is being used to drive anti-tumor activity against B cell malignancies. Methods: Patients (pts) with FL and MZL, stage 1-3A, and HLA-A2, are eligible. In the safety lead-in pts with relapsed/refractory (R/R) disease were given EO2463 SC q2 weeks (w) x 4, then q4w, for a max of 12 months; at w7 lenalidomide (20 mg/day for 21/28 days up to 12 cycles) is added (EL), and if no complete remission (CR) at w19, rituximab (375 mg/m 2 IV, q1w x 4, then q4w x 4) is also added (ER 2 ). Doses evaluated: 150 μg and 300μg/peptide. Results: 3 pts received 150 μg/peptide and 6 pts 300 μg/peptide (EO2463 1 pat, EL 2 pts, ER 2 6 pts): 2 MZL, 7 FL pts with median 2 lines (range 1-4) of prior systemic therapy. No related grade ≥3 adverse events were seen with EO2463 monotherapy. Most common related events were grade 1 to 2 local administration site reactions in 5/9 pts. Adverse events during combination treatment were as expected for R 2 . PET-CT on w6 after EO2463 monotherapy suggested clinical activity in 4/9 pts (1 PR, 1 pt size reduction 15%, 1 pt 20% reduced tracer uptake, 1 pt 5/6 target lesions reduced metabolic activity). Overall objective responses (OR) were seen in 6/9 pts (67%; 1 st OR on EO2463 1 pat, EL 4 pts, ER 2 1 pat), with CR in 5/9 (56%) pts; median time to response was 18w (range 8-43w), response ongoing in 5 pts, range 24-76w. Expansion of specific CD8+ T cells against mimic peptides and targeted B cell antigens were detected in all responding pts, incl. 2 pts with no measurable B cells at baseline (prior anti-CD20). Expansion of specific T cells was detected at w5 in 5/6 pts and was maintained as long as currently tested (up to w94, 43w after last EO2463 dose). No decline in expansions were seen after start rituximab. Conclusions: EO2463 (300 μg/peptide) monotherapy, EL, and ER 2 are well tolerated, with encouraging clinical activity with EO2463 monotherapy and with subsequent CR in 5/9 pts on combo. Rapid and durable expansion of specific CD8+ T cells was seen in all responding pts, consistent with the preclinical hypothesis. Additional cohorts investigate EO2463 alone or in combination in newly diagnosed or R/R pts. Results will be reported at the meeting. Clinical trial information: NCT04669171 .
antibodies
2026-09-13 | Primary Extranodal Marginal Zone Lymphoma of the Breast: A Case Report Highlighting the Clinicopathological Paradigm of an Indolent B-Cell Neoplasm
Primary or secondary lymphoma of the breast is an uncommon entity, accounting for less than 0.5% of all breast malignancies and approximately 1-2% of extranodal lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most frequently reported histological subtype. Marginal zone B-cell lymphoma involving the breast is exceedingly rare, particularly in patients with a prior history of DLBCL. The present case describes an unusual occurrence of synchronous second primary lymphoid neoplasm of breast in a patient previously treated for DLBCL, highlighting its diagnostic rarity. The authors report a rare case of a 57-year-old female with a past history of DLBCL, diagnosed two years ago on histopathological examination of excised lymph node over left neck region. Patient received chemoradiotherapy post-diagnosis and had recovered completely. She now presented with bilateral breast lumps and an additional lump in the left axillary region. An initial histopathological diagnosis of Non-Hodgkin’s Lymphoma of breast was made which needed further immunophenotypic characterisation. Immunohistochemistry (IHC) was done which showed strong positivity for CD45, CD19, CD20, PAX5, Bcl2, Ki-67 which confirmed the diagnosis of Marginal Zone B-cell Lymphoma, emphasising diagnostic challenges. Post histopathological diagnosis and immunohistochemistry, patient received targeted therapy along with chemotherapy to which she responded well. The present case is noteworthy because of the uncommon involvement of both breasts and the axillary region in a patient with a prior diagnosis of DLBCL, suggesting potential disease recurrence or extranodal extension.
2026-09-10 | Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.
Mosunetuzumab is highly effective against many B-cell lymphomas, but longitudinal immune changes induced by intermittently dosed CD20×CD3 bispecific antibodies remain incompletely characterized. We performed immune profiling of peripheral blood samples from patients receiving fixed-duration (6 months) subcutaneous mosunetuzumab for previously untreated follicular or marginal zone lymphoma on a phase 2 clinical trial (NCT04792502). Analyses included flow cytometry, cytokine profiling, and RNA-seq of isolated CD8+ T-cells with TCR repertoire inference. Early (at 3 weeks) on-treatment samples showed broad cytokine induction, CD8+ T-cell redistribution with decreased TEMRA cells and increased CD27+CD62L+ transitional effector memory-like cells, increased PD-1 and LAG-3 expression, and induction of CD8+ transcriptional programs consistent with activation, proliferation, exhaustion priming, and SREBF2-regulated cholesterol metabolism. By mid-treatment (at 3 months), activation-associated features contracted toward baseline, with no evidence of phenotypic exhaustion, though with persistent overexpression of LAG3, HAVCR2, and LAYN on RNA-seq, as well as sustained SREBF2 activation. CD8+ T-cell clonality increased at mid-treatment compared with baseline and higher clonality was associated with early clinical complete response. Mosunetuzumab also induced indirect NK-cell activation and expansion, including skewing toward CD56dimCD16bright effector state. HLA-DR upregulation on NK cells correlated with early increases in NK-activating plasma cytokines, and higher NK-cell count at mid-treatment was associated with complete response. Together, these findings define a CD8+ effector-remodeling state on mosunetuzumab therapy, characterized by clonal expansion, selective inhibitory receptor expression, sustained activation of cholesterol biosynthesis, and cytokine-linked engagement of innate immune mechanisms, providing a framework for potential strategies to support T-cell function and enhance bispecific antibody efficacy.
2026-06-29 | CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with limited curative treatment options. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) has recently been implicated in B-cell receptor signaling in MCL. We evaluated CEACAM1 expression by immunohistochemistry across MCL and other mature B-cell neoplasms, including small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). We retrospectively analyzed 164 lymphoma cases, 35 MM cases, and 2 plasmacytomas. CEACAM1 expression was assessed on tissue microarrays by immunohistochemistry and scored using a prespecified dichotomous cutoff. In DLBCL, CEACAM1 status was correlated with cell-of-origin classification and targeted mutational data. CEACAM1 was expressed in 27 of 30 MCL cases (90%), higher than in the other lymphoma subtypes combined (35%; P < .0001). Expression was also seen in SLL (20/30, 67%), MM (23/35, 66%), MZL (8/22, 36%), and DLBCL (19/82, 23%). In DLBCL, expression was more frequent in germinal center B-cell subtype than activated B-cell subtype cases (30% vs 13%; P = .023). Within sequenced DLBCL cases, CEACAM1 expression was associated with BCL2 and TNFRSF14 mutations. In MM, CEACAM1 expression was not significantly associated with recurrent cytogenetic abnormalities, although a nonsignificant trend toward higher expression in t(11;14) cases (75% vs 53%, Fisher exact P = .28). CEACAM1 is frequently expressed in MCL and in subsets of other mature B-cell neoplasms and MM. These findings support further investigation of CEACAM1 as a biologically relevant marker and potential therapeutic target in selected lymphoid malignancies.
2026-05-13 | Beyond Hypersplenism: Splenic Marginal Zone Lymphoma in an Older Adult with Hemoglobin E/Beta-Thalassemia.
With improvements in blood safety and availability, along with broad access to safe and effective iron chelation, outcomes for patients with thalassemia have greatly improved over recent decades. Previously a predominantly pediatric condition, thalassemia is now increasingly encountered in an aging population. We describe an adult man with HbE/β-thalassemia whose course was complicated by progressive splenomegaly and cytopenias, initially attributed to his underlying thalassemia. Further evaluation, however, revealed splenic marginal zone lymphoma. After the initiation of anti-B-cell therapy, he experienced rapid clinical improvement and was able to avoid surgical splenectomy. This case highlights how complications ascribed to thalassemia can overlap with other diagnoses that may become more prevalent with age, and demonstrates the importance of maintaining a broad differential when symptoms progress despite appropriate thalassemia-directed management.
2026-05-11 | Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report.
Marginal zone lymphomas (MZL) are indolent lymphomas that may undergo transformation into aggressive lymphomas, most frequently diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (LONCA) is an antibody-drug conjugate used in the treatment of relapsed/refractory large B-cell lymphomas. Here we present the clinical case of a patient with nodal transformed DLBCL and concomitant bone marrow involvement by indolent lymphoma successfully treated with LONCA. However the therapy was discontinued after six cycles as the patient developed treatment-related bone marrow aplasia. This case raises concerns about prolonged hematologic toxicity of LONCA, particularly in patients with pre-existing marrow involvement while highlights the potential of this drug to induce deep and durable response, even after limited exposure.
other
2026-09-24 | Longitudinal single-cell and spatial transcriptomics reveals intratumor heterogeneity, therapeutic response, and comparative value of canine marginal zone lymphoma.
Diffuse B-cell lymphomas are the most prevalent canine hematologic malignancies, and their clinical presentation resembles that of human B-cell non-Hodgkin lymphomas (NHLs). However, a lack of a clear subtyping framework perpetuates imprecise treatment approaches that fail to address mechanisms of therapy resistance. Here, we employed deep phenotyping via serial sampling and longitudinal transcriptomics to evaluate intratumoral composition and therapy response in a 6-year-old neutered male goldendoodle with stage 5A marginal zone lymphoma (MZL). Following sequential treatment consisting of a single IV dose of oncolytic vesicular stomatitis virotherapy (VSV) and standard CHOP chemotherapy 30 days later, we performed scRNAseq on seven serial lymph node biopsies and spatial sequencing on a resection taken 10 days post-VSV treatment. B cells (>90%) comprised three transcriptionally distinct and temporally stable subpopulations, with specific copy number profiles and robust spatial organization despite disrupted lymph node architecture. Analysis across subpopulations revealed downregulation of the quiescence program including KLF2, suggesting similarity to KLF2-deficient human MZL. While VSV successfully reached target B cells, downstream transcriptional responses were predominantly localized to the T-cell compartment. T cells (≤6%) showed increased proliferation and upregulation of cytotoxicity markers post-VSV administration, enriching for leukocyte-mediated cytotoxicity pathways consistent with an anti-viral immune response. Ultimately, these results provide an in vivo proof-of-concept for the treatment paradigm in canine lymphoma, while emphasizing the need for improved subtyping frameworks and multidimensional treatment strategies targeting intratumoral heterogeneity.
2026-04-13 | Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma
Marginal zone lymphoma (MZL) is an indolent subtype of non-Hodgkin lymphoma with heterogeneous clinical features. First-line treatment typically involves anti-CD20 monoclonal antibodies with or without chemotherapy. Although Bruton’s tyrosine kinase (BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R) MZL, their role as first-line therapy remains unclear. This single-center retrospective study included 25 treatment-naïve patients with MZL who received orelabrutinib (150 mg once daily) plus either rituximab or obinutuzumab for 6 cycles, followed by orelabrutinib maintenance for up to 6 months. The primary endpoint was overall response rate (ORR), assessed according to the 2014 Lugano criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. The ORR was 96.0%, comprising 12 complete response (CR) and 12 partial response (PR), with 1 case of stable disease (SD). Among the 13 patients with ocular adnexal MZL (OAML), 5 achieved CR, and 8 achieved PR. In the rituximab subgroup (n = 10), 5 patients achieved CR and 5 achieved PR, whereas in the obinutuzumab subgroup (n = 15), 7 achieved CR, 7 achieved PR, and 1 had SD; there was no significant difference in CR rate between the 2 groups (50.0% vs 46.7%, p = 1.000). Treatment-related adverse events (AEs) occurred in 32.0% of patients, with neutropenia (20.0%) and thrombocytopenia (12.0%) being the most common. Grade 3 to 4 events occurred in 12.0% of patients, with no significant differences in safety profiles between the rituximab and obinutuzumab subgroups. In conclusion, CD20 monoclonal antibodies combined with orelabrutinib may represent a feasible, low-toxicity first-line option for MZL, with favorable short-term efficacy and tolerability observed in this cohort. These preliminary findings warrant confirmation in larger prospective randomized studies to establish long-term benefits and safety.
2026-04-03 | Primary esophageal marginal zone lymphoma with respiratory symptoms: a case report and review of the literature.
Primary esophageal lymphoma is a rare disease whose pathogenesis may be related to immune abnormalities. We report a case of primary esophageal marginal zone lymphoma (MZL) in the esophagus for 2 years, which initially presented with respiratory symptoms and was subsequently diagnosed by endoscopic ultrasound-guided fine-needle aspiration. A 68-year-old male presented with a 10-day history of cough, excessive sputum production, and wheezing after physical activity. Two years prior to this admission, the patient had sought medical attention at our hospital for fever and cough. After completing the relevant examinations, the preliminary diagnosis was considered to be a pulmonary infection, with the possibility of an esophageal neoplastic lesion. Upon readmission, a follow-up chest CT revealed thickening of the esophageal wall in multiple segments, which was more pronounced than it had been 2 years previously, and tracheal compression. Upper gastrointestinal endoscopy revealed a widespread, protruding lesion along the entire esophagus, with a smooth mucosal surface and no ulceration. Endoscopic ultrasound revealed the disappearance of the normal layered structure of the esophageal wall at the site of the lesion. PET-CT demonstrated uneven increased radioactive uptake throughout the esophagus. Bone marrow aspiration did not reveal any tumor involvement. Histopathological and immunohistochemical examinations revealed marginal zone lymphoma. Primary esophageal lymphoma has significant clinical heterogeneity, typically starting with progressive dysphagia and weight loss. This patient has a long history of atypical symptoms, representing the first case to present with respiratory symptoms without dysphagia. Due to the extremely low incidence of primary esophageal lymphoma and the lack of typical symptoms, imaging findings, and endoscopic manifestations, it is prone to misdiagnosis. Differential diagnosis is necessary to distinguish it from esophageal malignancies such as esophageal squamous cell carcinoma and esophageal adenocarcinoma, as well as benign esophageal conditions like esophagitis and esophageal tuberculosis. Performing endoscopic ultrasound-guided fine needle aspiration to complete pathological biopsy is crucial to reduce the risk of misdiagnosis and facilitate early diagnosis. Currently, after two courses of the G-CVP regimen (Obinutuzumab + Cyclophosphamide + Vincristine + Prednisone) demonstrated suboptimal efficacy, the treatment was switched to a triple combination of Obinutuzumab, Orelabrutinib, and Lenalidomide, which has now completed six courses.
2026-01-19 | Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib-rituximab.
Marginal zone lymphoma is the second most common subtype of indolent non-Hodgkin lymphoma. Its clinical manifestations are heterogeneous and largely determined by the involved site. Chylous ascites, as the initial presentation of marginal zone lymphoma, is extremely rare. We report a 79-year-old man who presented with rapidly progressive abdominal distension due to high-volume chylous ascites. Flow cytometry of the ascitic fluid revealed a monoclonal lambda-restricted B-cell population consistent with low-grade B-cell lymphoma. Bone marrow biopsy confirmed splenic marginal zone lymphoma. Initial rituximab monotherapy was ineffective; however, combination therapy with orelabrutinib and rituximab led to complete resolution of ascites after two cycles and marked disease control. At 6-month follow-up, the patient remained in remission. Clinicians should consider lymphoma in the differential diagnosis of unexplained chylous ascites. Prompt etiologic treatment can result in favorable outcomes even in elderly patients with advanced disease.
2025-11-03 | Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study
Abstract Background: Emerging evidence suggests that triple-combination regimens incorporating Bruton tyrosine kinase (BTK) inhibitors, CD20-targeted agents, and immunomodulatory drugs (e.g., lenalidomide) may exhibit promising antitumor activity in indolent B-cell non-Hodgkin lymphomas (B-NHLs). In this study, we evaluated the efficacy and safety of orelabrutinib plus obinutuzumab and lenalidomide(GOL regimen) as a first-line therapy for MZL patients, aiming to assess its potential as a chemotherapy-free treatment option. Methods: In this prospective single-arm multicenter phase II trial (NCT06454968), eligible treatment-naïve adults (≥18 years) with histologically confirmed marginal zone lymphoma requiring systemic therapy received six 21-day cycles of induction therapy (oral orelabrutinib 150 mg QD on days 1-21, intravenous obinutuzumab 1000 mg on day 1 of each cycle, and oral lenalidomide 25 mg QD on days 1-14) followed by six 28-day cycles of orelabrutinib monotherapy (150 mg QD). The primary endpoint of our study is complete response rate, secondary endpoints were overall response rate, duration of response, uMRD rate of SMZL by IgH-DNA sequencing, and safety. Results: As of August 1, 2025, a total of 23 patients were enrolled in the study. The median age was 60 years (range: 36-81) with a male-to-female ratio of 0.92:1. Subtype distribution included: MALT/EMZL (n=9, 39.1%), SMZL (n=9, 39.1%), and dissMZL (n=5, 21.8%). All patients had Ann Arbor stage IV disease, with 6 cases (26.1%) presenting B symptoms. The MZL-IPI score distribution was: 0 points in 6 cases (26.1%), 1-2 points in 14 cases (60.9%), and 3-5 points in 3 cases (13.0%). Monoclonal gammopathy was observed in 9 out of 19 evaluable patients. All splenic marginal zone lymphoma (SMZL) patients exhibited massive splenomegaly, with 4 out of 9 showing baseline leukocytosis (peak WBC count 387.5×10⁹/L, lymphocyte count 371.9×10⁹/L). To date, 10 patients have completed 6 cycles of the three-drug combination (GOL) regimen, while 5 patients have completed all treatment and entered the follow-up phase. Among 18 response-evaluable patients, the overall response rate (ORR) was 88.9% (16/18) and the complete response rate (CRR) was 72.2% (13/18). By subtype analysis:SMZL patients demonstrated excellent outcomes with 100% ORR (6/6) and 100% CRR (6/6), all achieving complete remission by cycle 3, including 5 cases (83.3%) attaining MRD negativity by IgH-DNA sequencing;MALT/EMZL patients showed 77.8% ORR (7/9) and 66.7% CRR (6/9);dissMZL patients achieved 100% ORR (3/3) but a lower CRR of 33.3% (1/3). With a median follow-up of 8.1 months (range 2.3-13.1 months), none of the responding patients experienced disease progression, and the median duration of response (DOR) has not been reached. Regarding safety, all-grade adverse events included: infusion-related reactions (6/23), thrombocytopenia (6/23), rash (5/23), herpes zoster (2/23), petechiae (2/23), leukopenia (1/23), influenza A pneumonia (1/23), and invasive pulmonary aspergillosis (1/23). Grade 3 adverse events were limited to infusion-related reactions (2/23), thrombocytopenia (2/23), and rash (2/23), with no grade 4-5 adverse events reported. Conclusion: This phase II study demonstrates that the novel triple-combination regimen shows promising efficacy in treatment-naïve MZL patients, with an impressive overall response rate (88.9%) and complete response rate (72.2%), particularly in SMZL patients who achieved 100% CR. The regimen exhibited a manageable safety profile with no grade 4-5 adverse events. Early MRD negativity in SMZL suggests potential for durable remissions. These results support further study of this chemotherapy-free approach.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
15 orphan drug designations for Marginal zone lymphoma, including 2 approved therapies.
15 orphan drug designations for Marginal zone lymphoma, including 2 approved therapies.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
tafasitamab-cxix | antibodies | FDA | Incyte Corporation | |
Gallium (68Ga) boclatixafortide | oligonucleotides | EMA | Pentixapharm AG | |
Zanubrutinib [Brukinsa] | small molecules | EMA | Beone Medicines Ireland Limited | |
Axicabtagene ciloleucel | cell therapies | EMA | Kite Pharma EU B.V. | |
Lutetium (177Lu) lilotomab satetraxetan | antibodies | EMA | — | Nordic Nanovector AS |
Parsaclisib | small molecules | EMA | Incyte Biosciences Distribution B.V. | |
Copanlisib [Aliqopa] | small molecules | EMA | Bayer AG | |
Ibrutinib [Imbruvica] | small molecules | EMA | Janssen Cilag International | |
Obinutuzumab [Gazyvaro] | antibodies | EMA | Roche Registration Limited | |
Lenalidomide [Revlimid] | small molecules | EMA | Celgene Europe B.V. | |
bendamustine for 50ml admixture [Bendeka] | small molecules | FDA | Approved | Eagle Pharmaceuticals, Inc. |
bendamustine hydrochloride [Treanda] | small molecules | FDA | Approved | Cephalon, Inc. |
Idelalisib | small molecules | EMA | Gilead Sciences International Limited | |
Idelalisib | small molecules | EMA | Gilead Sciences International Limited | |
Idelalisib | small molecules | EMA | Gilead Sciences International Limited |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.